Bulimia Nervosa Market to grow at a CAGR of 5.89% during 2025 to 2035; Driven by Rising Incidence of Bulimia Nervosa and Increasing Focus on Mental Health

As per Market Research Future(MRFR) analysis, the Bulimia Nervosa Market was estimated at USD 1.86 Billion in 2024 and is projected to grow from USD 1.97 Billion in 2025 to USD 3.491 Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 5.89% during the forecast period 2025–2035. The market growth is largely attributed to an increased focus on mental health, the rising incidence of bulimia nervosa, advancements in treatment modalities, growing support networks, and regulatory support and funding initiatives.

The key players recognized by Market Research Future(MRFR) in the Bulimia Nervosa Market include Eli Lilly and Company (US), Pfizer Inc. (US), AstraZeneca PLC (GB), Bristol-Myers Squibb Company (US), GlaxoSmithKline PLC (GB), Johnson & Johnson (US), Novartis AG (CH), Sanofi S.A. (FR), and Takeda Pharmaceutical Company Limited (JP). These companies focus on innovative therapies, research and development initiatives, and strategic partnerships to strengthen their market positions.

Market Highlights

The Bulimia Nervosa Market is witnessing robust growth fueled by changing consumer behavior, increasing awareness of mental health issues, and the convenience offered by digital therapeutics and telehealth services. In 2024, the market size was recorded at USD 1.86 Billion, expanding to USD 1.97 Billion in 2025, and it is anticipated to reach USD 3.491 Billion by 2035. This expansion is supported by factors such as growing mental health education, technological integration in treatment, and a shift toward holistic approaches.

Moreover, the ongoing trend of technological integration, such as telehealth services and mobile applications for monitoring eating behaviors, is encouraging individuals to explore diverse support options.

Consumer demand for higher accessibility, early intervention, and patient-centric care is further driving providers to develop platforms that align with strict clinical standards. Technological advancements in orchestration and digital tools are also enhancing performance and reliability. The presence of strong healthcare infrastructure, coupled with the increasing penetration of insurance coverage, is expected to bolster market expansion over the coming decade.

Segment Analysis

The Bulimia Nervosa Market is segmented by diagnosis type, treatment type, age group, gender, and regional.

By diagnosis type, including Clinical Assessment, Psychological Evaluation, and Self-Reported Questionnaire, the market shows distinct performance metrics. Clinical Assessment remains the largest segment, capturing the dominant position as it encompasses comprehensive evaluations by healthcare professionals that facilitate accurate diagnosis. Psychological Evaluation and Self-Reported Questionnaire types have shown growth while remaining smaller in market share. Self-Reported Questionnaire is emerging as a vital and fastest-growing tool for initial screenings and follow-up assessments, especially in telehealth settings.

By treatment type, including Psychotherapy, Medication, Nutritional Counseling, and Support Groups, demand patterns vary significantly. Psychotherapy leads the market as the largest and dominant segment, driven by its foundational role in cognitive-behavioral therapy for addressing underlying psychological issues. Medication options represent an emerging and fastest-growing avenue within the treatment landscape, showing promising results when used in tandem with psychotherapy. Nutritional counseling and support groups contribute significantly by providing essential resources and community support.

By age group, including Children, Adolescents, Adults, and Older Adults, adolescents account for the largest share as the dominant segment due to heightened body image pressures and developmental challenges. Children and older adults represent smaller proportions of the market. The adult demographic represents the fastest growing and emerging group, exhibiting increasing rates of diagnosis reflective of broader awareness.

By gender, including Female, Male, and Non-Binary, females constitute the largest and dominant segment, driven by higher prevalence rates and targeted public awareness campaigns. Males represent a smaller segment that is emerging and fastest growing, witnessing a surge in recognition, diagnosis, and fading social stigma.

Regional Analysis

Regionally, the Bulimia Nervosa Market is segmented into North America, Europe, South America, Asia Pacific, and Middle East and Africa.

North America is the largest market for treatment, accounting for approximately 45% of the global market share, driven by increasing mental health awareness, advancements in treatment options, and supportive regulatory frameworks. Europe holds the second-largest share at approximately 30% of the global market, supported by government initiatives and active promotion of research and development.

Asia-Pacific is emerging as a significant market accounting for about 20% of the global market share, driven by changing lifestyles and rising disposable incomes. Middle East and Africa represent an untapped market holding approximately 5% of the global market share, where government initiatives are expected to catalyze future growth.

Key Findings of the Study

• The Bulimia Nervosa Market was estimated at USD 1.86 Billion in 2024, projected at USD 1.97 Billion in 2025, and expected to reach USD 3.491 Billion by 2035.


• The market registers a compound annual growth rate of 5.89% across the forecast period from 2025 to 2035.


• Clinical Assessment is the largest diagnosis segment, while Self-Reported Questionnaire is the fastest-growing.


• Psychotherapy leads as the largest treatment type, while Medication represents the fastest-growing option.


• North America dominates with approximately 45% of the global market share, while Asia-Pacific exhibits significant emerging potential.